RIPK1

Overview

RIPK1 (receptor-interacting serine/threonine protein kinase 1) encodes a key regulator of cell death pathways including apoptosis and necroptosis. In CLL, RIPK1 was identified as a novel driver candidate based on recurrent mutations at functionally relevant sites, with roles in cell cycle regulation and apoptosis.

Alterations observed in the corpus

  • Identified as a novel CLL driver candidate in WES of 160 CLL tumors (Broad Institute cohort); RIPK1 mutations implicate cell cycle and apoptosis pathways in CLL pathogenesis PMID:23415222

Cancer types (linked)

  • CLL: novel driver candidate; functional validation in independent cohorts still needed PMID:23415222

Co-occurrence and mutual exclusivity

  • No specific co-occurrence or mutual exclusivity patterns reported in the corpus.

Therapeutic relevance

  • RIPK1 inhibitors are in development for inflammatory diseases; relevance to CLL treatment requires investigation.

Open questions

  • Validation of RIPK1 as a true CLL driver in independent cohorts is needed; the study flagged it as a candidate pending further confirmation PMID:23415222

Sources

This page was processed by entity-page-writer on 2026-05-07.